Sabas, Shella Mae G.
HRN: 21-88-19 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/08/2022
CO-AMOXICLAV 625MG (TAB)
09/08/2022
09/15/2022
PO
625mg
BID
NSVD WITH 3RD DEGREE LACERATION AND REPAIR
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes